Oncotarget · 2016 · 62 citations · 26 references
MedicineHematologyOncologyCancer ImmunologyCarcinogenesisChemotherapyBiliary Tract CancerImmuno-oncology BiomarkersMalignant NeoplasmsTumor-infiltrating LymphocytesCancer-associated NeutrophilsClinical Grading SystemsDynamic ChangeNeutrophil-to-lymphocyte RatioPlatelet-to-lymphocyte RatioSystemic Inflammation MarkersTumor-associated Neutrophils
// Kyoung-Min Cho 1,3 , Hyunkyung Park 1 , Do-Youn Oh 1,2 , Tae-Yong Kim 1 , Kyung-Hun Lee 1,2 , Sae-Won Han 1,2 , Seock-Ah Im 1,2 , Tae-You Kim 1,2 and Yung-Jue Bang 1,2 1 Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea 2 Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea 3 Department of Internal Medicine, School of Medicine, Kyung Hee University, Seoul, Republic of Korea Correspondence to: Do-Youn Oh, email: // Keywords : inflammation, prognosis, advanced biliary tract cancer, neutrophil-to-lymphocyte ratio Received : September 06, 2016 Accepted : November 24, 2016 Published : November 30, 2016 Abstract Background and Purpose: Systemic inflammation is known to promote carcinogenesis in biliary tract cancer (BTC). Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are indicative of systemic inflammation. We evaluated the clinical significance of systemic inflammation measured by NLR and PLR in patients with advanced BTC. Additionally, we also co-analyzed the dynamics of NLR and PLR during chemotherapy. Methods: We reviewed 450 patients with unresectable BTC receiving palliative chemotherapy. NLR and PLR were obtained before initiation of palliative chemotherapy. Changes in NLR, PLR were obtained by subtracting the initial value from the value obtained after progression of chemotherapy. Results: Higher systemic inflammation status also had relation with a primary tumor site ( p = 0.003) and higher levels of CEA ( p = 0.038). The ROC cut-off values of NLR and PLR for predicting overall survival (OS) were 3.8 and 121, respectively. Patients with a high NLR or PLR had worse OS independently in multivariate analysis (6.90 vs . 9.80 months, p = 0.002; 7.83 vs . 9.90 months, p =0.041, respectively). High NLR with increased NLR after chemotherapy is associated with worse OS and progression-free survival (PFS) ( p < 0.001, p = 0.013 respectively). Results are similar for PLR. Conclusion: Systemic inflammation represented by NLR and PLR, predicts the OS of patients with advanced BTC who are receiving palliative chemotherapy. In addition, considering NLR/PLR with a dynamic change of NLR/PLR during chemotherapy might help to predict a more accurate prognosis.
26
Ahmedin Jemal, Rebecca L. Siegel, Elizabeth Ward et al. · CA A Cancer Journal for Clinicians · 2007 · 7.5K citations · Full text
Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update
Shahid A. Khan, Brian R Davidson, Robert Goldin et al. · Gut · 2012 · 793 citations · Full text
Riccardo Dolcetti, Alessandra Viel, Claudio Doglioni et al. · American Journal Of Pathology · 1999 · 477 citations · Full text